Health Condition 1: H350- Background retinopathy and retinalvascular changes
Conditions
Interventions
Intervention1: INTRAVITREAL BEVACIZUMAB
: dosage of 1.25 mg/0.05 ml,frequency of 3 injections in 6 months,Intravitreal route of administration,6 months total duration of therapy
Control Intervention1:
Sponsors
Department of Ophthalmology
Eligibility
Inclusion criteria
Inclusion criteria: 1. All consecutive cases of Type 2 DM, between age group 40-65 years, attending Retina Clinic of Department of Ophthalmology, K.G.M.U., Lucknow 2. In asymmetrical involvement, the eye with more severe form of the disease will be included
Exclusion criteria
Exclusion criteria: 1.Patients with any other ocular or systemic disease which can affect the retinal vasculature( Ischemic heart disease) 2. Previous intravitreal injection(s), ophthalmic surgical or laser interventions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Restoration Of Outer And Inner Retinal Layers Following Intravitreal Bevacizumab AdministrationTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Restoration Of Outer ,Inner Retinal Layers And Ellipsoid Zone Following Intravitreal BevacizumabTimepoint: 6 MONTHS | — |
Countries
India
Contacts
Public ContactSandeep Saxena
King Georges medical University Lucknow
Outcome results
None listed